OS Therapies FDA Meeting Request Granted
April 22, 2025
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
July 28, 2021
Related Post
-
-
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
April 21, 2025
-
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
April 16, 2025
-
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company
April 16, 2025